Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Apixaban for the treatment of venous thromboembolic events in paediatric patients: an open-label, multicentre, randomised, controlled descriptive trial.
Journal: The Lancet. Haematology
Published: November 15, 2025
Post-authorization safety study to assess the risk of diabetic ketoacidosis among type 2 diabetes mellitus patients treated with ertugliflozin compared to patients treated with other antihyperglycaemic agents in a Medicare and Medicaid population.
Journal: Diabetic medicine : a journal of the British Diabetic Association
Published: October 13, 2025
Association of Ertugliflozin on Kidney Outcomes in People After and Without an Interval Cardiovascular Event: Observations From the VERTIS CV Trial.
Journal: American journal of kidney diseases : the official journal of the National Kidney Foundation
Published: March 12, 2025
Heart failure outcomes captured by adverse event reporting in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial.
Journal: European journal of heart failure
Published: June 27, 2024
Cardiovascular and Renal Outcomes with Ertugliflozin by Baseline Use of Renin-Angiotensin-Aldosterone System Inhibitors or Diuretics, Including Mineralocorticoid Receptor Antagonist: Analyses from the VERTIS CV Trial.
Journal: Kidney diseases (Basel, Switzerland)
Published: June 18, 2024
Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV.
Journal: The Journal of clinical endocrinology and metabolism
Published: September 13, 2022
Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial.
Journal: Sleep & breathing = Schlaf & Atmung
Published: February 01, 2022
Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
Journal: Circulation
Published: October 07, 2020
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
Journal: The New England journal of medicine
Published: September 23, 2020
Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV).
Journal: American heart journal
Published: July 07, 2018
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.
Journal: The New England journal of medicine
Published: March 18, 2017
Last Updated: 09/26/2026